Corinnova
CorInnova is developing a minimally invasive, non-blood contacting cardiac assist device aimed at treating acute heart failure. The device is designed to increase cardiac output, promote cardiac restoration, and reduce adverse events associated with traditional blood-contacting devices. Supported by significant investments and numerous awards, CorInnova is at the forefront of innovative heart failure treatment technology.
Industries
Nr. of Employees
small (1-50)
Corinnova
Patents
Products
Minimally invasive non-blood-contacting cardiac assist implant
A collapsible, epicardial thin-film implant with internal conforming chambers and a self‑deploying frame that provides biventricular mechanical assistance via synchronized pneumatic inflation without contacting blood.
CorInnova device
A cardiac assist device designed for short-term support in Bridge to Decision/Recovery patients, bi-ventricular heart failure patients, anticoagulation intolerant patients, chemotherapy-induced heart failure patients, and patients with short term viral heart infections. It provides biventricular cardiac assist without blood contact and aims to expand the market by offering treatment options for patients ineligible for current cardiac assist technologies.
Minimally Invasive Non-blood Contacting Cardiac Assist Device
A minimally invasive, non-blood contacting cardiac assist device designed to treat acute heart failure by gently compressing the heart to increase cardiac output without touching the blood.
Minimally invasive non-blood-contacting cardiac assist implant
A collapsible, epicardial thin-film implant with internal conforming chambers and a self‑deploying frame that provides biventricular mechanical assistance via synchronized pneumatic inflation without contacting blood.
CorInnova device
A cardiac assist device designed for short-term support in Bridge to Decision/Recovery patients, bi-ventricular heart failure patients, anticoagulation intolerant patients, chemotherapy-induced heart failure patients, and patients with short term viral heart infections. It provides biventricular cardiac assist without blood contact and aims to expand the market by offering treatment options for patients ineligible for current cardiac assist technologies.
Minimally Invasive Non-blood Contacting Cardiac Assist Device
A minimally invasive, non-blood contacting cardiac assist device designed to treat acute heart failure by gently compressing the heart to increase cardiac output without touching the blood.
Services
Design and fabrication of soft‑robotic thin‑film cardiac assist prototypes and execution of benchtop hemodynamic performance tests.
Execution of acute and chronic ovine heart-failure studies to evaluate deployment feasibility, safety, removability, hemocompatibility, and therapeutic effect.
Design and oversight of pneumatic driver hardware and control algorithms to achieve cardiac-synchronized inflation of implant chambers.
Conducting development and manufacturing activities within FDA- and CE-mandated medical device design control systems to support regulatory submissions.
Design and fabrication of soft‑robotic thin‑film cardiac assist prototypes and execution of benchtop hemodynamic performance tests.
Execution of acute and chronic ovine heart-failure studies to evaluate deployment feasibility, safety, removability, hemocompatibility, and therapeutic effect.
Design and oversight of pneumatic driver hardware and control algorithms to achieve cardiac-synchronized inflation of implant chambers.
Conducting development and manufacturing activities within FDA- and CE-mandated medical device design control systems to support regulatory submissions.
Expertise Areas
- Minimally invasive cardiac assist device development
- Soft-robotic and thin-film implant engineering
- Preclinical large-animal cardiovascular testing
- Pneumatic actuation and cardiac-synchronized control systems
Key Technologies
- Soft-robotic direct cardiac compression
- Thin-film collapsible implant structures
- Minimally invasive self‑deploying delivery frames
- Pneumatic actuation synchronized to cardiac cycle
News & Updates
Various news articles and features highlighting CorInnova's achievements, awards, and technological advancements.
BioNTX names CorInnova a 2024 Rising Star and presents at the 2024 iC³® Life Science & Healthcare Innovation Summit.
CorInnova joins the MedTech Innovator's 2022 Cohort, the world's largest MedTech accelerator program.
CorInnova is selected as a finalist at the prestigious annual pediatric medical device competition.
William Altman presents at TCT 2021 session on emerging technological trends in interventional heart failure.
CorInnova presents at the Life Science Innovation Summit 2021.
Various news articles and features highlighting CorInnova's achievements, awards, and technological advancements.
BioNTX names CorInnova a 2024 Rising Star and presents at the 2024 iC³® Life Science & Healthcare Innovation Summit.
CorInnova joins the MedTech Innovator's 2022 Cohort, the world's largest MedTech accelerator program.
CorInnova is selected as a finalist at the prestigious annual pediatric medical device competition.
William Altman presents at TCT 2021 session on emerging technological trends in interventional heart failure.
CorInnova presents at the Life Science Innovation Summit 2021.